Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 19/20 | 0.71 |
| ▸ | STAT3 | P40763 | 2/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | JAK1 | P23458 | 1/20 | 0.56 |
| ▸ | STAT1 | P42224 | 1/20 | 0.56 |
| ▸ | JAK3 | P52333 | 1/20 | 0.56 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28975910 | 0.91 | TYK2 (0.73) | TYK2STAT3JAK2JAK1STAT1 | |
| SCHEMBL30227341 | 0.87 | TYK2 (0.60) | TYK2STAT3JAK2JAK1STAT1 | |
| SCHEMBL20524882 | 0.87 | TYK2 (0.75) | TYK2STAT3JAK2JAK1STAT1 | |
| SCHEMBL31004921 | 0.85 | TYK2 (0.52) | TYK2STAT3JAK2JAK1STAT1 | |
| SCHEMBL30392130 | 0.85 | TYK2 (0.53) | TYK2STAT3JAK2JAK1STAT1 | |
| SCHEMBL26116374 | 0.84 | TYK2 (0.54) | TYK2STAT3JAK2JAK1JAK3 | |
| SCHEMBL30227307 | 0.84 | TYK2 (0.71) | TYK2STAT3JAK1 | |
| SCHEMBL25232915 | 0.84 | TYK2 (0.71) | TYK2STAT3JAK1 | |
| SCHEMBL30204885 | 0.84 | TYK2 (0.53) | TYK2STAT3JAK2JAK1STAT1 | |
| SCHEMBL30227331 | 0.84 | TYK2 (0.73) | TYK2STAT3JAK2JAK1STAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479831-B2 | Substituted N(-methyl-D3)pyridazine-3-carboxamide or M-(methyl-D3)-nicotinamide compounds as IL-12, IL-23 and/or IFNα modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-11-25 | — | — | US | disclosed |
| US-20230167092-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2023-06-01 | — | — | US | disclosed |
| EP-4143180-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | Bristol-Myers Squibb Company (US) | 2023-03-08 | — | — | EP | disclosed |
| CN-115715287-A | Substituted N- (methyl-d 3) pyridazine-3-carboxamide or N- (methyl-d 3) -nicotinamide compounds as IL-12, IL-23 and/or IFN alpha modulators | 百时美施贵宝公司 | 2023-02-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167092-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | JAK3, TYK2, IRAK3 | TYK2 2/4885STAT3 7/4885JAK2 26/4885 |
| US-12479831-B2 | Substituted N(-methyl-D3)pyridazine-3-carboxamide or M-(methyl-D3)-nicotinamide compounds as IL-12, IL-23 and/or IFNα modulators | TYK2, IRAK3, JAK3 | TYK2 1/4885STAT3 7/4885JAK2 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.